PT-141 (Bremelanotide)
Melanocortin agonist for libido.
- Sizes available
- 10mg
- Lab certificate (COA)
- Supplier-published sample
· Research-grade only · Not for human consumption · 21+ ·
FDA-approved female libido therapy (Vyleesi). Melanocortin pathway.
Mechanism · Bremelanotide. MC3R/MC4R agonist. FDA 2019 (HSDD pre-menopausal women).
Best for. Not for.
Best for
- HSDD in pre-menopausal women (per the Vyleesi label)
- Central libido pathway for users who do not respond to PDE5 inhibitors
- On-demand use roughly 45 minutes before activity
Not for
- Uncontrolled HTN. Transient BP elevation
- Cardiovascular disease history
- Pregnancy (Vyleesi label contraindication)
- Users concerned about dark skin or mole discoloration
Mechanism, dose, ramp, risk.
- Mechanism
- MC4R agonist. Central libido enhancement.Source · PEPVERA editorial
- Target dose
- 1-2 mg, subq, on demand.Source · PEPVERA editorial
- Ramp
- On demand.Source · PEPVERA editorial
- Risks
- Nausea, transient HTN.Source · PEPVERA editorial
Compared to its siblings.
PT-141 (Bremelanotide)
FDA-approved female libido therapy (Vyleesi). Melanocortin pathway.
Pros
- · FDA approval (Vyleesi 2019), unlike melanotan-2.
- · No mole discoloration, unlike melanotan-2.
Cons
- · No tan side effect, unlike melanotan-2.
- · Higher cost than melanotan-2.
- · Central mechanism, no peripheral vascular action like tadalafil.
Melanotan 2
Non-selective MC1R + MC4R agonist. Libido and tan side effects. Not approved.
Pros
- · Cost-effective
- · Tan + libido dual effect
Cons
- · No FDA approval
- · Stronger nausea and mole discoloration
See Melanotan 2 →
Tadalafil (Research)
PDE5 inhibitor. Peripheral vasodilation (centered on male ED).
Pros
- · FDA Cialis 2003 large evidence base
Cons
- · Mechanism completely different (vascular)
See Tadalafil (Research) →
COA per supplier
Published, in-house, or shipment-time
Each supplier declares its own HPLC floor and COA policy. The per-supplier verifier appears on the certificate page; refund and shipping terms vary by supplier and are shown on the supplier listing.
Compare 7 suppliers
| Supplier | Price | COA | Ships | |
|---|---|---|---|---|
| Pure Peptide UKUK | $20$2.00/mg · 10mg | In-house COA | 4 days | Out of stock |
| NG PeptidesUS | $24.99$2.50/mg · 10mg | Sample COA published | 3 days | Out of stock |
| Verified PeptidesUS | $34.99$3.50/mg · 10mg | Sample COA published | 3 days | |
| Ameano PeptidesUS | $44$4.40/mg · 10mg | Sample COA published | 2 days | |
| Ascension PeptidesUS | $48$4.80/mg · 10mg | Sample COA published | 3 days | |
| SwissChemsUS | $49.99$5.00/mg · 10mg | COA with shipment | 3 days | |
| Royal PeptidesUS | $50$5.00/mg · 10mg | Sample COA published | 3 days |
Direct from foundry. Slower than domestic resellers; consistency is the trade. Insulated packaging, tracked from departure to doorstep. Replacement issued on damage.
Week 1–2
1-2 mg, subq, on demand.
Initiation
Week 3–4
1-2 mg, subq, on demand.
Signal emerges
Week 5–8
1-2 mg, subq, on demand.
Hold
Week 9–12
Cycle review
Assess
Draw 20 units.
1 mg = 0.20 mL at 5.00 mg/mL. 10.0 doses per vial.
drive · I · Verified Peptides
PT-141 (Bremelanotide) · 10mg